Citizens, a US-based investment bank, has lowered its price target for Belgian-Dutch biotech firm Argenx to $932 per share, down from $1,106, citing valuation concerns. The adjustment comes as Argenx shares have surged in 2026 on the back of strong sales of its autoimmune drug Vyvgart and promising trial results for new indications.
The analysts noted that while Argenx’s fundamental outlook remains robust, the stock’s recent rally has pushed its valuation to levels that may already reflect much of the expected growth. The new target still implies a modest upside from current trading levels, but the reduction signals a more cautious near-term stance.
For UK investors, Argenx is listed on the Nasdaq but is followed by European funds and some UK pension portfolios with exposure to global biotech. The sector has been volatile this year, with the Nasdaq Biotechnology Index up roughly 8% year-to-date, but facing headwinds from interest rate uncertainty and regulatory shifts.
Argenx reported first-quarter revenues of $610m, beating analyst estimates, and recently secured European approval for Vyvgart in a new autoimmune condition. However, competition from rivals such as Johnson & Johnson and UCB has intensified, keeping pressure on pricing and market share.
Analysts at other firms have maintained a mixed view: Jefferies recently reiterated a buy rating with a $1,200 target, while Morgan Stanley downgraded the stock to equal-weight in June. The divergence reflects the challenge of valuing high-growth biotech in a rising rate environment.
For UK pension holders, the Argenx target cut is a reminder that even successful biotech stocks can face valuation corrections. Diversification across sectors and geographies remains key, as single-stock volatility can impact fund performance.